ACADMEMIC DEBATE
JIANG Ning, QI Chun-hui, CAO Liang, CHEN Lan-ying, GU Jin-hui, KANG Yong, Inkyeom KIM, LIAN Xiao-yuan, LU Yin, LYU Gui-yuan, NIE Ke, QI Yun, Valérie SCHINI-KERTH, Michael SPEDDING, Cherry WAINWRIGHT, WANG Yue-hua, XIAO Wei, YANG Yong, YU Lin-zhong, ZHANG Dan-shen, ZHANG Yong-he, ZHOU Wen-xia, DU Guan-hua, ZHANG Yong-xiang
The 2017 China (Lianyungang) International Medical Technology Conference was held in Lianyungang, Jiangsu Province during November 15-17, 2017. During this conference, the Division for Traditional Chinese Medicine and Natural Products Pharmacology of Chinese Pharmacological Society (CNPHARS) and Jiangsu Kanion Pharmaceutical Co. Ltd. jointly held the Forum on R&D and Internationalization of New Drugs and Health Products of Traditional Chinese Medicine. The forum was co-chaired by Professor ZHANG Yong- xiang, President of CNPHARS, Chair of Division for Traditional Chinese Medicine and Natural Products Pharmacology of CNPHARS, and Chair of the Natural Product Section of International Union of Basic & Clinical Pharmacology (IUPHAR), Professor DU Guan-hua, former President of CNPHARS and Vice-Chair of Division for Traditional Chinese Medicine and Natural Products Pharmacology of CNPHARS, and Dr. XIAO Wei, Chairman of the Board of Jiangsu Kanion Pharmaceutical Co. Ltd. and Vice- Chair of Division for Traditional Chinese Medicine and Natural Products Pharmacology of CNPHARS. More than 70 scholars attended the forum, including four foreign experts [Michael SPEDDING, Secretary-General of IUPHAR; Professor Valérie B. SCHINI- KERTH, Vice-Chair of the Natural Product Section of IUPHAR; Professor Cherry WAINWRGHT, Director of Centre for Natural Product Drugs of Robert Gordon University; Professor InKyeom KIM, Director of the Korean Society of Pharmacology], members of the Division for Traditional Chinese Medicine and Natural Products Pharmacology of CNPHARS and leading researchers at Jiangsu Kanion Pharmaceutical Co., Ltd. GU Jin-hui, Director of the Division of National Science and Technology Major Project for Drug Innovation, Department of Health Science, Technology and Education, National Health and Family Planning Commission of the People′s Republic of China was also invited to attend the forum. Representatives discussed the R&D and internationalization of new drugs and health products of traditional Chinese medicine. The summary of views and advice of some experts was published here for the purpose of promoting domestic and overseas academic exchange, and playing an active role in improving the level of R&D and internationalization of new drugs and health products of traditional Chinese medicine in China.